-
10 possible signs of Alzheimer's — and how the disease affects Hispanic people
The Alzheimer’s Association created a list of early signs of the disease or other types of dementia. In the United States, the disease disproportionately affects Hispanic patients.
-
Bob Barker died from Alzheimer's disease, death certificate states
Barker died at age 99 from Alzheimer’s disease and other contributing factors, as outlined in his death certificate.
-
Gales Ferry's John Clark prepares for 25th annual ride for Alzheimer's awareness
August is always an important month for Gales Ferry’s John Clark. The 81-year-old is getting ready for his annual Ride to End Alzheimer’s. This year marks the 25th straight year he has rode his bike with the hopes of raising money to find a cure. “This is a passion for me,” said Clark, who says he has raised about $17,000...
-
Gales Ferry's John Clark prepares for 25th annual ride for Alzheimer's awareness
August is always an important month for Gales Ferry’s John Clark. The 81-year-old is getting ready for his annual Ride to End Alzheimer’s.
-
Some insurers won't cover new Alzheimer's treatment shown to slow decline
Some private insurers are balking at paying for the first drug fully approved to slow mental decline in Alzheimer’s patients.
-
Finger prick blood test could revolutionize Alzheimer's disease diagnosis, research shows
Researchers say the finger prick would be quick and non-invasive, and samples could be taken at home, then easily transported for testing.
-
Finger prick blood test could revolutionize Alzheimer's disease diagnosis, research shows
Researchers say the blood test could be taken at home and would indicate changes related to the disease.
-
Study shows Eli Lilly's Alzheimer's drug slows memory decline but with safety risks
If U.S. regulators approve, the drug would be only the second Alzheimer’s treatment convincingly shown to delay the mind-robbing disease — after rival Leqembi. Both drugs pose a serious safety concern — brain swelling and bleeding.
-
FDA approves Alzheimer's drug Leqembi, paving way for broader Medicare coverage
Leqembi slowed cognitive decline in a clinical trial, but the treatment is expensive and carries serious risks of brain swelling and bleeding.
-
Alzheimer's drug gets FDA panel's backing, setting the stage for broader use
U.S. health advisers are backing the full approval of an Alzheimer’s drug that received preliminary approval last year. A panel of advisers to the Food and Drug Administration on Friday voted in favor of the infused medication from drugmakers Eisai and Biogen. The FDA granted accelerated approval in January based on early results suggesting the drug could modestly slow Alzheimer’s....
-
New Alzheimer's Treatment Sparks Hope, But Comes With Obstacles
Some people living with Alzheimer’s disease are feeling hopeful about a new medication on the market. It is called Leqembi. However, even though it received accelerated approval from the FDA, it is not covered by the Centers for Medicare and Medicaid Services. Nonetheless, one Connecticut woman managed to get the high-cost medication for her mother. With Mother’s Day this...
-
New Alzheimer's Treatment Sparks Hope, But Comes With Obstacles
Leqembi aims to slow cognitive decline, but costs $26,500 a year and is not covered by insurance.
-
Experimental Drug Slows Worsening Effects of Alzheimer's
Eli Lilly and Co. said Wednesday its experimental Alzheimer’s drug appeared to slow worsening of the mind-robbing disease in a large study. NBC 5’s Bianca Castro talked with Frisco neurologist Dr. Aimee Garza about how it works.
-
Connecticut Whale Set to Host Alzheimer's Awareness Game
The Connecticut Whale welcomes the Toronto Six this weekend for two games in Simsbury. Saturday’s contest is also a game for a cause near to some players’ hearts. It’s their annual Alzheimer’s Awareness Game in partnership with the Alzheimer’s Association of Connecticut. For players like Janine Weber, it’s a game she looks forward to, thinking about how Alzheimer’s has...
-
Yale Doctor Discusses Recently Fast-Tracked Alzheimer's Drug
A doctor at Yale New Haven Health discusses the Alzheimer’s drug Lecanemab, which the FDA recently granted accelerated approval.
-
CT Man in Alzheimer's Clinical Trial, Family Weigh in on New Experimental Drug
A local family is waiting on a decision from the FDA on whether or not to grant accelerated approval to a drug called Lecanemab. That decision is expected to come Friday. It would impact the Sirois family in Kensington, along with the 6.5 million Americans living with Alzheimer’s Disease. Lecanemab is one of the first experimental drugs to show potential…
-
CT Man in Alzheimer's Clinical Trial, Family Weigh in on New Experimental Drug
The FDA is expected to decide whether or not to grant Lecanemab accelerated approval to fill an unmet medical need.
-
Experimental Drug Shows Signs of Slowing Cognitive Decline in Alzheimer's Patients, Study Finds
New data shows an experimental Alzheimer’s drug modestly slowed the brain disease’s inevitable worsening. The next question is how much difference that might make in people’s lives.
-
Wesleyan University Professor Studies Alzheimer's Disease Using Cells From Patients
Dr. Alison O’Neil is turning skin cells from Alzheimer’s patients into brain cells to study the early markers of the illness and hopefully stop neuron degeneration before it starts.
-
New Services, Technology to Improve At-Home Alzheimer's Care
Assisted Living Services has developed some new services and technology to improve at-home care for people with Alzheimer’s.